India's decision to cap trade margins on 137 non-scheduled anti-cancer medicines has already delivered measurable relief, with 70 companies slashing maximum retail prices by an average of 20% to 70% across 120 medicines — generating estimated patient savings of ₹3,357.49 crore, according to an official factsheet released on Friday, 6 November 2026. The steepest single reduction recorded stands at 96.45%, and the revised prices are set to take effect from 9 November 2026.

What the NPPA Cap Does

The National Pharmaceutical Pricing Authority (NPPA) on 17 October 2026 capped trade margins — including on patented drugs — at 30% of the maximum retail price (MRP). The intervention targets excessive mark-ups accumulated across distributors, stockists, retailers, and hospital pharmacies, which critics and patient groups had long flagged as a primary driver of unaffordable cancer treatment costs in India.

Trade margin is defined as the difference between the price a manufacturer charges a stockist or distributor and the highest price — the MRP — that a patient ultimately pays, excluding Goods and Services Tax (GST). In practice, this gap had grown large enough to price many patients out of essential therapies.

How the Savings Figure Was Calculated

The ₹3,357.49 crore estimate represents the aggregate difference between original and revised prices, applied to the volume of medicines sold between April 2025 and March 2026. Manufacturers are required to recalculate their MRPs using their average distributor prices from March 2026. Notably, free medicines distributed under patient assistance programmes and direct government sales are excluded from this calculation.

As of 4 November 2026, price revisions for 120 of the 137 targeted drugs had been completed and published on the NPPA website, which is updated on a rolling basis as companies submit revised figures.

Disclosure and Compliance Rules for Companies

Under the new framework, companies must notify the NPPA of their revised prices, publish the reductions in newspapers, post them on their official websites, and communicate the changes to all retailers and hospital pharmacies. Patients can independently verify updated prices through the NPPA website and the official Pharma Sahi Daam mobile application.

Background: Building on a 2019 Pilot

This is not the first time the government has used Trade Margin Rationalisation (TMR) as a pricing tool. A pilot intervention in 2019 covered 42 non-scheduled anti-cancer drugs and successfully reduced patient costs, establishing the proof of concept that the current, broader rollout builds upon. The expansion from 42 to 137 medicines reflects both the policy's proven track record and the sustained pressure from state governments, patient advocacy groups, and civil society organisations about the gap between procurement prices and MRPs.

With implementation underway and the remaining 17 medicines still pending revised submissions from manufacturers, the full savings potential of the scheme is expected to be realised in the coming weeks.